Comprehensive Report on DYV-700/DYV702 for Acute Gout Pain

I. Introduction

DYV-700 is an investigational therapeutic agent formulated as a topical cream for transdermal administration, primarily developed for the management of pain associated with acute gout flares.[1] The development is spearheaded by Dyve Biosciences, Inc., a clinical-stage biotechnology company.[7] It is pertinent to note a nomenclature inconsistency within the source materials; the compound studied in the key clinical trial (NCT04130204) is referred to as both DYV-700 [2] and DYV702.[10] One source clarifies that DYV-700 and DYV-702 are alternative names for a sodium bicarbonate transdermal formulation.[18] This report will use "DYV-700/DYV702" to reflect this ambiguity while acknowledging they likely refer to the same entity. The primary therapeutic goal of DYV-700/DYV702 is to offer rapid pain relief and shorten the duration of acute gout attacks, addressing a significant unmet need in current gout management.[1]

II. Developer Profile: Dyve Biosciences and Technology Platform

Dyve Biosciences is a clinical-stage biotechnology company focusing on leveraging its proprietary transdermal delivery technology, known as the DMAX platform, across various therapeutic areas, including immunology and oncology.[10] A core scientific strategy for the company involves pH modulation, particularly targeting acidic microenvironments associated with disease progression in cancer and inflammatory conditions.[26]